Final checkup of neoplastic DNA replication: Evidence for failure in decision-making at the mitotic cell cycle checkpoint G1/S

Experimental Hematology

Volumn 36, Issue 11, 2008, Pages 1403-1416

  Prindull, Gregor ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; GENOMIC DNA; HISTONE; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR; VIRUS DNA; DNA;

CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL AGING; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL IMMORTALIZATION; CELL PROLIFERATION; CHROMATIN; CHROMATIN STRUCTURE; CPG ISLAND; DECISION MAKING; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; EMBRYONIC STEM CELL; GENE REPRESSION; GENETIC STABILITY; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; INFORMATION RETRIEVAL; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MEDLINE; MEMORY CELL; MITOSIS; NEOPLASM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RETROVIRUS; REVIEW; TRANSCRIPTION REGULATION; VIRUS INFECTIVITY; ANIMAL; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS; GENOMIC INSTABILITY; METABOLISM; TELOMERE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DNA METHYLATION; DNA REPLICATION; DNA, NEOPLASM; EMBRYONIC STEM CELLS; EPIGENESIS, GENETIC; G1 PHASE; GENOMIC INSTABILITY; HUMANS; NEOPLASTIC STEM CELLS; S PHASE; TELOMERE; TRANSCRIPTION, GENETIC;

EID: 53749094148     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.07.009     Document Type: Review

References (284)

1. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
2. Haan de G., Nijhof W., and Zant van G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood 89 (1997) 1543-1550
3. Chen J., Astle C.M., and Harrison D.E. Development and aging of primitive hematopoietic stem cells in BALB/cBy mice. Exp Hematol 27 (1999) 928-935
4. Marley S.B., Lewis J.L., Davidson R.J., et al. Evidence for a continuous decline in hematopoietic cell function from birth: application to evaluating bone marrow failure in children. Br J Haematol 106 (1999) 162-166
5. Zant van G., and Liang Y. The role of stem cells in aging. Exp Hematol 31 (2003) 659-672
6. Liang Y., Zant van G., and Szilvassy S.J. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 106 (2005) 1479-1487
7. Xing Z., Ryan M.A., Daria D., et al. Increased hematopoietic stem cell mobilization in aged mice. Blood 108 (2006) 2190-2197
8. Colvin G.A., Dooner M.S., Dooner G.J., et al. Stem cell continuum: directed differentiation hotspots. Exp Hematol 35 (2007) 96-107
9. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 3 (2002) 662-673
10. Prindull G., and Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 103 (2004) 2892-2899
11. Jepsen K., and Rosenfeld M.G. Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci 115 (2002) 689-698
12. Kel-Margoulis O.V., Tschekmenev D., Kel A.E., et al. Composition-sensitive analysis of the human genome for regulatory signals. In Silico Biol 3 (2003) 145-171
13. Suzuki Y., Yamashita R., Shirota M., et al. Large-scale collection and characterization of promotors of human and mouse genes. In Silico Biol 4 (2004) 429-444
14. Campbell K.H.S., Loi P., Otaegui P.J., and Wilmut I. Cell cycle co-ordination in embryo cloning by nuclear transfer. Rev Reprod 1 (1996) 40-46
15. Humpherys D., Eggan K., Akutsu H., et al. Epigenetic instability in ES cells and cloned mice. Science 293 (2001) 95-97
16. Wilmut I., Beaujean N., de Sousa P.A., et al. Somatic cell nuclear transfer. Nature 419 (2002) 583-586
17. Tamada H., and Kikyo N. Nuclear reprogramming in mammalian somatic cell nuclear cloning. Cytogenet Genome Res 105 (2004) 285-291
18. Dean W., Santos F., and Reik W. Epigenetic reprogramming in early mammalian development and following somatic nuclear transfer. Semin Cell Develop Biol 14 (2003) 93-100
19. Niemann H., Tian X.C., King W.A., and Lee R.S.F. Epigenetic reprogramming in embryonic and foetal development upon somatic cell nuclear transfer cloning. Reproduction 135 (2008) 151-163
20. Pardal R., Clarke M.F., and Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3 (2003) 895-902
21. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
22. Hong D., Gupta R., Ancliff P., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319 5861 (2008) 336-339
23. Prindull G. Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells?. Exp Hematol 33 (2005) 738-746
24. Knudson A.G. Mutation and cancer. Proc Natl Acad Sci U S A 68 (1971) 820-823
25. Feinberg A.P., Ohlsson R., and Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7 (2006) 21-33
26. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
27. Dreesen O., and Brivanlou A.H. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3 (2007) 7-17
28. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
29. Edelman E.J., Guinney J., Chi J.T., Febbo P.G., and Mukherjee S. Modeling cancer progression via pathway dependencies. PloS Comput Biol 4 2 (2008) e28
30. Rossi D.J., Bryder D., Zahn J.M., et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 102 (2005) 9194-9199
31. Bagnara G.P., Bonsi L., Strippoli P., et al. Hematopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hematopoietic growth factors and remodeling of cytokine network. J Gerontol Biol Sci 55A (2000) B61-B70
32. Lundberg A.S., and Weinberg R.A. Control of the cell cycle and apoptosis. Eur J Cancer 35 (1999) 531-539
33. Lowe S.W., Cepero E., and Evan G. Intrinsic tumor suppression. Nature 432 (2004) 307-315
34. Ben-Porath I., and Weinberg R.A. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 37 (2005) 961-976
35. Bartek J., and Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19 (2007) 238-245
36. Shiloh Y. ATM and related protein kinases: safegurading genome integrity. Nat Rev Cancer 3 (2003) 155-168
37. Lieb J.D., Beck S., Bulyk M.L., et al. Applying whole-genome studies of epigenetic regulation to study human disease. Cytogenet Genome Res 114 (2006) 1-15
38. Jaenisch R., and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genet Suppl 33 (2003) 245-254
39. Cutfield W.S., Hofman P.L., Mitchell M., and Morison I.M. Could epigenetics play a role in the developmental origins of health and disease?. Pediatr Res 61 (2007) 68R-75R
40. Reik W., Dean W., and Walter J. Epigenetic reprogramming in mammalian development. Science 293 (2001) 1089-1093
41. Hasty P., Campisi J., Hoeijmakers J., Steeg van H., and Vijg J. Aging and genome maintenance: lessons from the mouse?. Science 299 (2003) 1355-1359
42. Barker D.J. The fetal and infant origins of adult disease. BMJ 301 (1990) 1111
43. Crews D., and McLachlan J.A. Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology 147 Suppl (2006) S4-S10
44. Coe C.L., Lubach G.R., and Shirtcliff E.A. Maternal stress during pregnancy predisposes for iron deficiency in infant monkeys impacting innate immunity. Pediatr Res 61 (2007) 520-524
45. Lanzuolo C., and Orlando V. The function of the epigenome in cell reprogramming. Cell Mol Life Sci 64 (2007) 1043-1062
46. McEvoy T.G., Ashworth C.J., Rooke J.A., and Sinclair K.D. Consequences of manipulating gametes and embryos of ruminant species. Reprod Suppl 61 (2003) 167-182
47. Gao S., and Latham K.E. Maternal and environmental factors in early cloned embryo development. Cytogenet Genome Res 105 (2004) 279-284
48. Fraga M.F., Ballestar E., Paz M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102 (2005) 10604-10609
49. Wong A.H.C., Gottesman I.L., and Petronis A. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Human Mol Genet 14 (2005) R11-R18
50. Petronis A. Epigenetics and twins: three variations on the theme. Trends Genet 22 (2006) 347-350
51. Bohr V.A. DNA damage and its processing. Relation to human disease. J Inherit Metab Dis 25 (2002) 215-222
52. Berardi P., Russell M., El-Osta A., and Riabowol K. Functional links between transcription, DNA repair and apoptosis. Cell Mol Life Sci 61 (2004) 2173-2180
53. Boer de J., Andressoo J.O., Wit de J., et al. Premature aging in mice deficient in DNA repair and transcription. Science 296 (2002) 1276-1279
54. Syljuasen R.G., Jensen S., Bartek J., and Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polio-like kinase 1 kinases. Cancer Res 66 (2006) 10253-10257
55. Hutter G., Scheubner M., Zimmermann Y., et al. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantel cell lymphoma. Genes Chromosomes Cancer 45 (2006) 203-210
56. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22 (2007) 91-103
57. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early pathway addiction. Nature Rev Cancer 6 (2006) 107-116
58. Jones P.A. Overview of cancer epigenetics. Semin Hematol 42 Suppl (2005) S3-S8
59. Widschwendter M., Fiegl H., Egle D., et al. Epigenetic stem cell signature in cancer. Nat Genet 39 (2007) 157-158
60. Ringrose L., and Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38 (2004) 413-443
61. Lee T.I., Jenner R.G., Boyer L.A., et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125 (2006) 301-313
62. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20 (2006) 1123-1136
63. INK4a. Nature 443 (2006) 421-426
64. Burdon T., Smith A., and Savatier P. Signalling, cell cycle and pluripotency in embryonal stem cells. Trends Cell Biol 12 (2002) 432-438
65. Hardy K., Handyside A.H., and Winston R.M.L. The human blastocyst: cell number, death and allocation during late preimplantation development in vitro. Development 107 (1989) 597-604
66. Jurisicova A., Rogers I., Fasciani A., Casper R.F., and Varmuza S. Effect of maternal age and conditions of fertilization on programmed cell death during murine preimplantation embryo development. Mol Hum Reprod 4 (1998) 139-145
67. Draper J.S., Moore H.D., Ruban L.N., Gokhale P.J., and Andrews P.W. Culture and characterization of human embryonic stem cells. Stem Cells Dev 13 (2004) 325-336
68. Rhee I., Bachman K.E., Park B.H., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416 (2002) 552-556
69. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299 (2003) 1753-1755
70. Mantel C., Guo Y., Lee M.R., et al. Checkpoint-apoptosis uncoupling in human and mouse embryonic stem cells: a source of karyotypic instability. Blood 109 (2007) 4518-4527
71. Yu H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol 14 (2002) 706-714
72. Bharadwaj R., and Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 23 (2004) 2016-2927
73. Kops G.J.P.L., Foltz D.R., and Cleveland D.W. Lethality to human cancer cells through masssive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101 (2004) 8699-8704
74. Boyapati A., Yan M., Peterson L.F., Biggs J.R., LeBeau M.M., and Zhang D.E. A leukemic fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood 109 (2007) 3963-3971
75. Wiemels J.L., Xiao Z., Buffler P.A., et al. In utero origin of t(8;21) AML1-Eto translocations in childhood acute myeloid leukemia. Blood 99 (2002) 3801-3805
76. Greaves M.F., Maia A.T., Wiemels J.L., and Ford A.M. Leukemia in twins: lessons in natural history. Blood 102 (2003) 2321-2333
77. Scintu M., Vitale R., Prencipe M., et al. Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer Lett 254 (2007) 298-307
78. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 16 (2002) 6-21
79. Kirkland M.A., Quesenberry P.J., and Roeder I. discrete stem cells: subsets or a continuum? [letter]. Blood 108 (2006) 3949
80. Paro R. Propagating memory of transcriptional states. Trends Genet 11 (1995) 295-297
81. Issa J.P. Age-related epigenetic changes and the immune system. Clin Immunol 109 (2003) 103-108
82. Shen X., Xiao H., Ranallo R., Wu W.H., and Wu C. Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates. Science 299 (2003) 112-114
83. Ling J.Q., and Hoffman A.R. Epigenetics of long-range chromatin interactions. Pediatr Res 61 (2007) 11R-16R
84. Surani M.A. Reprogramming of genome function through epigenetic inheritance. Nature 414 (2001) 122-128
85. Boyer L.A., Lee T.I., Cole M.F., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122 (2005) 947-956
86. Cavalli G. Chromatin as a eukaryotic template of genetic information. Curr Opin Cell Biol 14 (2002) 269-278
87. Simon J.A., and Tamkun J.W. Programming off and on states in chromatin: mechanisms of polycomb and thrithorax group complexes. Curr Opin Genet Dev 12 (2002) 210-218
88. Wolffe A.P., and Guschin D. Review: chromatin structural features and targets that regulate transcription. J Struct Biol 129 (2000) 102-122
89. Lund A.H., and Lohuizen van M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16 (2004) 239-246
90. Erhardt S., Lyko F., Ainscough J.F.X., Surani M.A., and Paro R. Polycomb-group proteins are involved in silencing processes caused by a transgenic element from the murine imprinted H19/Igf2 region in Drosophila. Dev Genes Evol 213 (2003) 336-344
91. Trimarchi J.M., and Lees J.A. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3 (2002) 11-20
92. Müller H., Bracken A.P., Vernell R., et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15 (2001) 267-285
93. Henikoff S., and Ahmad K. Assembly of variant histones into chromatin. Ann Rev Cell Dev Biol 21 (2005) 133-153
94. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
95. Tomasi T.B., Magner W.J., and Khan A.N.H. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 55 (2006) 1159-1184
96. Kamminga L.M., Bystrykh L.V., Boer de A., et al. The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107 (2006) 2170-2179
97. INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem 281 (2006) 24790-24802
98. Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., and Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23 (2004) 5759-5769
99. Pirrotta V. Chromatin complexes regulating gene expression in Drosophila. Curr Opin Genet Dev 5 (1995) 466-472
100. Viré E., Brenner C., Deplus R., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
101. Voncken J.W., Schweizer D., Aagaard L., Sattler L., Jantsch M.F., and Lohuizen van M. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci 112 (1999) 4627-4639
102. Caldas C., and Aparicio S. Cell memory and cancer-the story of the trithorax and polycomb group genes. Cancer Metastasis Rev 18 (1999) 313-329
103. Piotrowski A. Genes Chromosomes Cancers 45 (2006) 656-667
104. Krivtsov A.V., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukemia stem cell initiated by MLL-AF9. Nature 442 (2006) 818-822
105. Valk-Lingbeek M.E., Bruggeman S.W.M., and Lohuizen van M. Stem cells and cancer: the polycomb connection. Cell 118 (2004) 409-418
106. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N Engl J Med 355 (2006) 1253-1261
107. Allsopp R.C., Vaziri H., Patterson C., et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 89 (1992) 10114-10118
108. Khoo C.M., Carrasco D.R., Bodenberg M.W., Paik J.H., and DePinho R.A. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomere-deficient mouse. Proc Natl Acad Sci U S A 104 (2007) 3931-3936
109. Campisi J., Kim S., Lim C.S., and Rubio M. Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol 36 (2001) 1619-1637
110. Hug N., and Linger J. Telomere length homeostasis. Chromosoma 115 (2006) 413-425
111. Jacob N.K., Lescasse R.L., Linger B.R., and Price C.M. Tetrahymena POT1a regulates telomere length and prevents activation of a cell cycle checkpoint. Mol Cell Biol 27 (2007) 1592-1601
112. Glover L., Alsford S., Beattie C., and Horn D. Deletion of a trypanosome telomere leads to loss of silencing and progressive loss of terminal DNA in the absence of cell cycle arrest. Nucl Acids Res 35 (2007) 872-880
113. Itahana K., Campisi J., and Dimri G. Mechanisms of cellular senescence in human and mouse cells. Biogerontology 5 (2004) 1-10
114. Johnson F.B., Sinclair D.A., and Guarente L. Molecular biology of aging. Cell 96 (1999) 291-302
115. Multani A.S., and Chang S. WRN at telomeres: implications for aging and cancer. J Cell Sci 120 (2007) 713-721
116. Lange de T., and Jacks T. For better or worse? Telomerase inhibition and cancer. Cell 98 (1999) 273-275
117. Caslini C., and Hess J.L. MLL modulates telomere length in mammalian cells. Blood 108 11, part 1 (2006) 626a, Abstract 2209
118. Yui J., Chiu C.P., and Lansdorp P.M. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 91 (1998) 3255-3262
119. Serakinci N., Hoare S.F., Kassem M., Atkinson S.P., and Keith W.N. Telomerase promotor reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen Med 1 (2006) 125-131
120. Beliveau A., Bassett E., Lo A.T., et al. p53-dependent integration of telomere and growth factor deprivation signals. Proc Natl Acad Sci U S A 104 (2007) 4431-4436
121. Beauséjour C.M., Krtolica A., Galimi F., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22 (2003) 4212-4222
122. Holt S.E., Glinsky V.V., Ivanova A.B., and Glinsky G.V. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 25 (1999) 241-248
123. Maser R.S., Wong K.K., Sahin E., et al. DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol Cel Biol 27 (2007) 2253-2265
124. Chin L., Artandi S.E., Shen Q., et al. p53 deficiency rescues the adverse effects of telomerase loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97 (1999) 527-538
125. Nguyen D.C., and Crowe D.L. Intact functional domains of the retinoblastoma gene product (pRb) are required for downregulation of telomerase activity. Biochim Biophys Acta 1445 (1999) 207-215
126. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003) 194-198
127. Reddel R.R. The role of senescence and immortalization in carcinogenesis. Carcinogenesis 21 (2000) 477-484
128. Rudolph K.L., Millard M., Bosenberg M.W., and DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28 (2001) 155-159
129. Sharpless N.E., and DePinho R.A. Telomeres, stem cells, senescence, and cancer. J Clin Invest 113 (2004) 160-168
130. González-Suárez E., Samper E., Flores J.M., and Blasco M.A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 26 (2000) 114-117
131. Ji H.J., Rha S.Y., Jeung H.C., Yang S.H., An S.W., and Chung H.C. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat 93 (2005) 227-236
132. Guittat L., Alberti P., Gomez D., et al. Targeting human telomerase for cancer therapeutics. Cytotechnology 45 (2004) 75-90
133. Thelen P., Wuttke W., Jarry H., Grzmil M., and Ringert R.H. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 171 (2004) 1934-1938
134. Datta A., Bellon M., Sinha-Datta U., et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108 (2006) 1021-1029
135. Kim G.D., Ni J., Kelesoglu N., Roberts R.J., and Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 21 (2002) 4183-4195
136. Jones P.A., and Takai D. The role of DNA methylation in mammalian epigenetics. Science 293 (2001) 1068-1070
137. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12 (1998) 2245-2262
138. Rashidian J., Iyirhiaro G.O., and Park D.S. Cell cycle machinery and stroke. Biochim Biophys Acta 1772 (2007) 484-493
139. Bartek J., and Lukas J. Order from destruction. Science 294 (2001) 66-67
140. Devaskar S.U., and Raychaudhuri S. Epigenetics-a science of heritable biological adaptation. Pediatr Res 61 (2007) 1R-4R
141. Fischle W., Wang Y., and Allis C.D. Histone and chromatin cross-talk. Curr Opin Cell Biol 15 (2003) 172-183
142. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
143. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
144. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., and Ponte F.J. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci U S A 983 (2003) 84-100
145. Peterson C.L., and Laniel M.A. Histones and histone modifications. Curr Biol 14 (2004) R546-R551
146. 1/S transition. Bioinformatics 20 (2004) 1506-1511
147. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
148. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
149. Sudarsanam P., and Winston F. The Swi/Snf family: nucleosome-remodeling complexes and transcriptional control. Trends Genet 16 (2000) 345-351
150. Angelov D., Molla A., Perche P.Y., et al. The histone variant macroH2A interferes with transcription factor binding and SWI/SNF nucleosome remodeling. Mol Cell 11 (2003) 1033-1041
151. Kornberg R.D. The eukaryotic gene transcription machinery. Biol Chem 382 (2001) 1103-1107
152. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23 (2005) 3971-3993
153. Saunders A., Core L.J., and Lis J.T. Breaking barriers to transcription elongation. Mol Cell Biol 7 (2006) 557-567
154. Liu H., Takeda S., Cheng E.H.Y., and Hsieh J.D. Biphasic MLL takes helm at cell cycle control. Cell Cycle 7 (2008) 428-435
155. Sotillo E., Garriga J., Kurimchak A., and Grana X. Cyclin E and SV40 Small t Antigen cooperates to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J Biol Chem 283 (2008) 11280-11292
156. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13 (2003) 77-83
157. Stein G.H., Drullinger L.F., Soulard A., and Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19 (1999) 2109-2117
158. Alcorta D.A., Xiong Y., Phelps D., Hannon G., Beach D., and Barrett J.C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 93 (1996) 13742-13747
159. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 (2001) 731-737
160. Bates S., Phillips A.C., Clark P.A., et al. p14ARF links the tumour suppressors RB and p53. Nature 395 (1998) 124-125
161. Quelle D.E., Zindy F., Ashmun R.A., and Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83 (1995) 993-1000
162. ARF/p53-induced proliferative arrest. Cancer Cell 2 (2002) 55-65
163. ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2 (2000) 148-155
164. Gonzalez-Paz N., Chng W.J., McClure R.F., et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109 (2007) 1228-1232
165. Dib A., Barlogie B., Shaughnessy Jr. J.D., and Kuehl W.M. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 109 (2007) 1337-1338
166. INK4b gene. FEBS Lett 581 (2007) 1087-1092
167. Golubnitschaja O. Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids 32 (2007) 359-371
168. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
169. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
170. Azechi H., Nishida N., Fukuda Y., et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 60 (2001) 346-354
171. Chen S., Chen L., Le N.T., et al. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorgan Med Chem Lett 17 (2007) 2134-2138
172. Grillo M., Bott M.J., Khandke N., et al. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95 (2006) 185-194
173. Joshi K.S., Rathos M.J., Joshi R.D., et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 6 (2007) 918-925
174. Tagoh H., Melnik S., Lefevre P., Chong S., Riggs A.D., and Bonifer C. Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro. Blood 103 (2004) 2950-2955
175. Ezhevsky S.A., Nagahara H., Vocero-Akbani A.M., Gius D.R., Wei M.C., and Dowdy S.F. Hypo-phosphorylation of the retinoblastoma protein (pRB) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A 94 (1997) 10699-10704
176. Knudsen K.E., Weber E., Arden K.C., Cavenee W.K., Feramisco J.R., and Knudsen E.S. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene 18 (1999) 5239-5245
177. /BTG2/PC3 as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol 132 (2006) 417-426
178. Skp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110 (2007) 1631-1638
179. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
180. Narita M., Nunez S., Heard E., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003) 703-716
181. Imai M.A., Oda Y., Oda M., Nakanishi I., and Kawahara E. Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J Cancer Res Clin Oncol 130 (2004) 320-326
182. Vousden K.H. p53: death star. Cell 103 (2000) 691-694
183. Cip/Waf1 translocation correlate with caspase-3 activation in TGF-β1-induced apoptosis of HuH-7 cells. Apoptosis 9 (2004) 211-221
184. Khan S.H., Moritsugu J., and Wahl G.M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci U S A 97 (2000) 3266-3271
185. Varela I., Cadinanos J., Pendás A.M., et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 437 (2005) 564-568
186. ARF. Cell 103 (2000) 321-330
187. Dumble M., Moore L., Chambers S.M., et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 109 (2007) 1736-1742
188. Peterson E.J., Bögler O., and Taylor S.M. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res 63 (2003) 6579-6582
189. 2/M checkpoints. Genes Dev 16 (2002) 245-256
190. Rayman J.B., Takahashi Y., Indjeian V.B., et al. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 16 (2002) 933-947
191. Stanelle J., Stiewe T., Theseling C.C., Peter M., and Pützer B.M. Gene expression changes in response to E2F1 activation. Nucleic Acid Res 30 (2002) 1859-1867
192. ARF links the tumour suppressor p53 to Ras. Nature 395 (1998) 125-126
193. INK4a induces an age-dependent decline in islet regenerative potential. Nature 443 (2006) 453-457
194. INK4a expression decreases forebrain progenitors and neurogenesis during aging. Nature 443 (2006) 448-452
195. Frolov M.V., and Dyson N.J. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 117 (2004) 2173-2181
196. Bannister A.J., Schneider R., and Kouzarides T. Histone methylation: dynamic or static?. Cell 109 (2002) 801-806
197. Rea S., Eisenhaber F., O'Carroll D., et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406 (2000) 593-599
198. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 3 (2003) 253-266
199. Lachner M., and Jenuwein T. The many faces of histone lysine methylation. Curr Opin Cell Biol 14 (2002) 286-298
200. Grewal S.I.S., and Elgin S.C.R. Heterochromatin: new possibilities for the inheritance of structure. Curr Opin Genet Dev 12 (2002) 178-187
201. Bachman K.E., Park B.H., Rhee I., et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3 (2003) 89-95
202. Hendzel M.J., Wei Y., Mancini M.A., et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentrometric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106 (1997) 348-360
203. Hake S.B., Xiao A., and Allis C.D. Linking the epigenetic "language" of covalent histone modifications to cancer. Br J Cancer 90 (2004) 761-769
204. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 (2006) 1770-1783
205. Senese S., Zaragoza K., Minardi S., et al. Role for histone deacetylase 1 in human tumor proliferation. Mol Cell Biol 27 (2007) 4784-4795
206. Schneider R., Bannister A.J., and Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 27 (2002) 396-402
207. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 12 (2002) 198-209
208. Lee J.H., Hart S.R.L., and Skalnik D.G. Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 38 (2004) 32-38
209. Chang K.T., and Min K.T. Regulation of lifespan by histone deacetylase. Ageing Res Rev 1 (2002) 313-326
210. Görisch S.M., Wachsmuth M., Tóth K.F., Lichter P., and Rippe K. Histone acetylation increases chromatin accessibility. J Cell Sci 118 (2005) 5825-5834
211. Pandita T.K., Hunt C.R., Sharma G.G., and Yang Q. Regulation of telomere movement by telomere chromatin structure. Cell Mol Life Sci 64 (2007) 131-138
212. Godfrey K.M., Lillycrop K.A., Burdge G.C., Gluckman P.D., and Hanson M.A. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res 61 (2007) 5R-10R
213. Fraga M.F., Ballestar E., Villar-Garea A., et al. Loss of acetylation at Lys 16 and trimethylation at Lys 20 of histone H4 is a common hallmark of human cancer. Nat Genet 37 (2005) 391-400
214. Pruitt K., Zinn R.L., Ohm J.E., et al. Inhibition of SIRT1 reactivates cancer silenced genes without loss of promotor DNA hypermethylation. PLoS Genet 2 (2006) e40
215. WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promotor in human cervical cancer cells. Biochem Biophys Res Com 324 (2004) 860-867
216. Schmidt M., and Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10 (2007) 162-181
217. Lindemann R.K., Gabrielli B., and Johnstone R.W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3 (2004) 779-788
218. Gojo I., Jiemjit A., Trepel J.B., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 (2007) 2781-2790
219. Vlasáková J., Nováková Z., Rossmeislová L., Kahle M., Hozák P., and Hodný Z. Histone deacetylase inhibitors suppress IFNα-induced up-regulation of promyelocytic leukemia protein. Blood 109 (2007) 1373-1380
220. Florenes V.A., Skrede M., Jorgensen K., and Nesland J.M. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res 14 (2004) 173-181
221. Insinga A., Monestiroli S., Ronzoni S., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11 (2005) 71-76
222. Zhang K., Williams K.E., Huang L., et al. Histone acetylation and deacetylation: identification of acetylation and methylation sites of hela histone H4 by mass spectrometry. Mol Cell Proteomics 1 (2002) 500-508
223. Horn P.J., and Peterson C.L. Heterochromatin assembly: a new twist on an old model. Chromosome Res 14 (2006) 83-94
224. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32 (2004) 959-976
225. Kitabayashi I., Aikawa Y., Yokoyama A., et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia 15 (2001) 89-94
226. Zhang Y., and Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15 (2001) 2343-2360
227. Fischle W., Wang Y., Jacobs S.A., Kim Y., Allis C.D., and Khorasanizadeh S. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev 17 (2003) 1870-1881
228. Crawford B.D., and Hess J.L. MLL core components give the green light to histone methylation. ACS Chem Biol 1 (2006) 495-498
229. Yokoyama A., Wang Z., Wysocka J., et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24 (2004) 5639-5649
230. Lee J.H., and Skalnik D.G. CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set 1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J Biol Chem 280 (2005) 41725-41731
231. Dou Y., Milne T.A., Tackett A.J., et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121 (2005) 873-885
232. Milne T.A., Hughes C.M., Lloyd R., Yang Z., Rozenblatt-Rosen O., Dou Y., Schnepp R.W., Krankel C., LiVolsi V.A., Gibbs D., Hua X., Roeder R.G., Meyerson M., and Hess J.L. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 102 (2005) 749-754
233. Takai D., and Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 99 (2002) 3740-3745
234. Fröhling S., Scholl C., Bansal D., and Huntly J.P. HOX gene regulation in acute myeloid leukemia. Cell Cycle 6 (2007) 2241-2245
235. Ansari K.I., Mishra B.P., and Mandal S.S. Human CpG binding protein interacts with MLL1, MLL2 and hSet1 and regulates Hox gene expression. Biochim Biophys Acta 1779 (2008) 66-73
236. Caslini C., Yang Z., El-Osta M., Milne T.A., Slany R.K., and Hess J.L. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 67 (2007) 7275-7283
237. Daser A., and Rabbitts T.H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18 (2004) 965-974
238. Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., and Wolffe A.P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promotors. Nat Genet 25 (2000) 338-342
239. Bachman K.E., Rountree M.R., and Baylin S.B. Dnmt3a and Dnmt3b are transcription repressors that exhibit unique locatization properties to heterochromatin. J Biol Chem 276 (2001) 32282-32287
240. Schlesinger Y., Straussman R., Keshet I., et al. Polycomb-mediated methylation of Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39 (2007) 232-236
241. Fazzari M.J., and Greally J.M. Epigenomics: beyond CpG islands. Nat Rev Genet 5 (2004) 446-455
242. Ramsahoye B.H., Biniszkiewicz D., Lyko F., Clark V., Bird A.P., and Jaenisch R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 97 (2000) 5237-5242
243. Esteller M., and Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196 (2002) 1-7
244. Fuks F., Burgers W.A., Godin N., Kasai M., and Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 20 (2001) 2536-2544
245. Eden A., Gaudet F., Waghmare A., and Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300 (2003) 455
246. Gaudet F., Hodgson J.G., Eden A., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
247. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev 2 (2003) 245-261
248. Singhal R.P., Mays-Hoopes L.L., and Eichhorn G.L. DNA methylation in aging of mice. Mech Ageing Dev 41 (1987) 199-210
249. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promotor hypermethylation. N Engl J Med 349 (2003) 2042-2054
250. Kitajima K., Tanaka M., Zheng J., et al. Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2. Blood 107 (2006) 1857-1863
251. Suzuki M., Yamada T., Kihara-Negishi F., et al. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene 25 (2005) 2477-2488
252. INK4A characterize the major types of hematological malignancies. Cancer Res 57 (1997) 837-841
253. EL-Osta A. DNMT cooperativity-the developing links between methylation, chromatin structure and cancer. Bioessays 25 (2003) 1071-1084
254. Agrawal S., Hofmann W.K., Tidow N., et al. The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109 (2007) 3985-3905
255. Costello J.F., Frühwald M.C., Smiraglia D.J., et al. Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet 24 (2000) 132-138
256. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
257. Lippman Z., Gendrel A.V., Black M., et al. Role of transposable elements in heterochromatin and epigenetic control. Nature 430 (2004) 471-476
258. Kazazian Jr. H.H. Mobile elements: driver of genome evolution. Science 303 (2004) 1626-1632
259. Capy P., Gasperi G., Biémont C., and Bazin C. Stress and transposable elements: co-evolution or useful parasites?. Heredity 85 (2000) 101-106
260. Scholes D.T., Kenny A.E., Gamache E.R., Mou Z., and Curcio M.J. Activation of a LTR-retrotransposon by telomere erosion. Proc Natl Acad Sci U S A 100 (2003) 15736-15741
261. Han J.S., Szak S.T., and Boeke J.D. Transcriptional disruption by L1 retrotransposon and implications for mammalian transcriptomes. Nature 429 (2004) 268-274
262. Cheng C., Daigen M., and Hirochika H. Epigenetic regulation of the rice retrotransposon Tos17. Mol Gen Genomics 276 (2006) 378-390
263. Liu Z.L., Han F.P., Tan M., et al. Activation of a rice endogenous retrotransposon Tos17 in tissue culture is accompanied by cytosine demethylation and causes heritable alteration in methylation pattern of flanking genomic regions. Theor Appl Genet 109 (2004) 200-209
264. Denne M., Sauter M., Armbruester V., Licht J.D., Roemer K., and Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and Rec with the promyelocytic leukemia zinc finger protein. J Virol 81 (2007) 5607-5616
265. Parseval de N., and Heidmann T. Human endogenous retroviruses: from infectious elements to human genes. Cytogenet Genome Res 110 (2005) 318-332
266. Wang-Johanning F., Liu J., Rycaj K., et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer 120 (2006) 81-90
267. Lewitzky M., and Yamanaka S. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol 18 (2007) 467-473
268. Nelson P.N., Carnegie P.R., Martin J., et al. Demystified human endogenous retroviruses. J Clin Pathol Mol Pathol 56 (2003) 11-18
269. Büscher K., Trefzer U., Hofmann M., Sterry W., Kurth R., and Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 65 (2005) 4172-4180
270. Griffiths D.J. Endogenous retroviruses in the human genome sequence. Genome Biol 2 (2001) 1017.1-1017.5 reviews
271. Moyes D., Griffiths D.J., and Venables P.J. Insertional polymorphisms: a new lease of life for endogenous retroviruses in human disease. Trends Genet 23 (2007) 326-333
272. Bannert N., and Kurth R. Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci U S A 101 Suppl 2 (2004) 14572-14579
273. Gifford R., and Tristem M. The evolution, distribution and diversity of endogenous retroviruses. Virus Genes 26 (2003) 3,291-3,315
274. Prindull G.A., and Fibach E. Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells?. Exp Hematol 35 (2007) 691-701
275. Perez-Pomares J.M., and Munoz-Chapuli E. Epithelial-mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in metazoans. Anat Rec 268 (2002) 343-351
276. Duelli D.M., and Lazebnik Y.A. Primary cells suppress oncogene-dependent apoptosis. Nat Cell Biol 2 (2000) 859-862
277. INK4b. Mol Cell Biol 20 (2000) 2915-2925
278. Lotem J., and Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin Cancer Biol 12 (2002) 339-346
279. Araki H., Yoshinaga K., Boccuni P., Zhao Y., Hoffman R., and Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulation potential. Blood 109 (2007) 3570-3578
280. Lavelle D., Vaitkus K., Hankewych M., Singh M., and DeSimone J. Effect of 5-ara-2′-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the ε{lunate}-, γ-, and β-globin promoters in Papio anubis. Exp Hematol 34 (2006) 339-347
281. Waggoner D. Mechanisms of disease: epigenesis. Semin Pediatr Neurol 14 (2007) 7-14
282. Huntly B.J.P., and Gilliland D.G. Summing up cancer stem cells. Nature 435 (2005) 1169-1170
283. Jones R.J., Matsui W.H., and Smith B.D. Cancer stem cells: are we missing the target?. J Nat Cancer Inst 96 (2004) 583-585
284. Huff C.A., Matsui W., Smith B.D., and Jones R.J. The paradox of response and survival in cancer therapeutics. Blood 107 (2006) 431-434